MoonLake Immunotherapeutics

MLTX

Healthcare|Biotechnology|Switzerland

$20.36

+0.43 (+2.18%)

Tangible Book

$3.52

Earnings Power

$3.55

Clinical Trials (10)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06641076 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug	Arthritis, Psoriatic	P3	Active	960	RCT, Double-blind	Sonelokimab, Placebo
NCT06641089 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response	Arthritis, Psoriatic	P3	Recruiting	600	RCT, Double-blind	Sonelokimab, Placebo, Risankizumab
NCT06768671 An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)	Hidradenitis Suppurativa	P3	Active	35	Open-label	Sonelokimab
NCT06411899 A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Hidradenitis Suppurativa	P3	Completed	422	RCT, Double-blind	Sonelokimab, Placebo
NCT06411379 Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Hidradenitis Suppurativa	P3	Completed	418	RCT, Double-blind	Sonelokimab, Placebo
NCT07223138 A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis	Arthritis, Psoriatic	P3	By Invite	1,560	Open-label	Sonelokimab
NCT07007637 A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa	Hidradenitis Suppurativa	P3	By Invite	835	Open-label	Sonelokimab
NCT05640245 Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis	Arthritis, Psoriatic	P2	Completed	207	RCT, Double-blind	Sonelokimab, Placebo, Adalimumab
NCT05322473 Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa	Hidradenitis Suppurativa	P2	Completed	234	RCT, Double-blind	Sonelokimab (M1095), Adalimumab
NCT06994936 An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector	Relative Bioequivalence	P1	Completed	120	RCT, Open-label	Sonelokimab, Sonelokimab